SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-13-074385
Filing Date
2013-10-07
Accepted
2013-10-07 17:01:38
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13D a13-21844_6sc13d.htm SC 13D 50707
  Complete submission text file 0001104659-13-074385.txt   52515
Mailing Address 420 LEXINGTON AVENUE SUITE 1609 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 1609 NEW YORK NY 10170 212-297-0010
SYNERGY PHARMACEUTICALS, INC. (Filed by) CIK: 0001347613 (see all company filings)

IRS No.: 330505269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations

Mailing Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170 212-297-0020
ContraVir Pharmaceuticals, Inc. (Subject) CIK: 0001583771 (see all company filings)

IRS No.: 462783806 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13D | Act: 34 | File No.: 005-87637 | Film No.: 131139665
SIC: 2834 Pharmaceutical Preparations